NeuroPace to Participate in Upcoming Healthcare Conferences in September
22 août 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
13 août 2024 16h05 HE
|
NeuroPace, Inc.
-- Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 -- -- Increased full-year 2024 revenue guidance to $76 million to $78 million -- -- Demonstrated continued operating...
NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
23 juil. 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace to Participate in Two Healthcare Conferences in May
14 mai 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
17 avr. 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
05 mars 2024 16h05 HE
|
NeuroPace, Inc.
-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 -- -- Provides full-year 2024 revenue...
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
21 déc. 2023 07h07 HE
|
NeuroPace, Inc.
NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently...
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
19 déc. 2023 16h30 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
04 déc. 2023 17h07 HE
|
NeuroPace, Inc.
First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data...
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
01 déc. 2023 08h00 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...